TLDR: Claret Capital Partners has announced a €10 million growth investment in Yseop, a leader in generative AI for the life sciences and pharmaceutical sectors. This funding will fuel Yseop’s international expansion and accelerate the development of its enterprise-grade platform, Yseop Copilot, which automates regulatory content creation for major pharmaceutical companies like Eli Lilly and Novartis.
Claret Capital Partners has committed a significant €10 million growth investment to Yseop, a pioneering company in generative AI solutions for the life sciences and pharmaceutical industries. This strategic funding, announced on September 18, 2025, is earmarked to bolster Yseop’s global expansion initiatives and expedite the enhancement of its cutting-edge generative AI platform, Yseop Copilot.
Yseop Copilot is already a critical tool for leading pharmaceutical organizations, including industry giants like Eli Lilly and Novartis. The platform is designed to streamline the often-arduous process of creating complex clinical and regulatory documentation, such as Clinical Study Reports (CSRs), patient narratives, and Chemistry, Manufacturing, and Controls (CMC) submissions.
Antony Baker, Senior Investment Director at Claret Capital Partners, expressed enthusiasm for the partnership, stating, “We are delighted to invest in Yseop. Their team is building an exciting, highly innovative business, with a leading AI-powered platform that is helping some of the biggest names in pharma to deliver therapies faster to market. We very much look forward to being part of the growth journey from here.”
Emmanuel Walckenaer, CEO of Yseop, highlighted the timeliness of the investment: “This investment comes at a pivotal moment for our industry. As regulatory complexity increases and timelines tighten, the need for intelligent automation is only growing. Claret’s support allows us to accelerate innovation and deliver even greater value to our customers.”
The core of Yseop’s technology lies in its Composite AI architecture, which uniquely combines large language models with robust business logic and domain-specific rules. This ensures that all generated outputs are not only scientifically accurate but also fully compliant and audit-ready for highly regulated environments. The platform’s native integration with widely used tools like Microsoft Word and Veeva Vault allows life sciences companies to seamlessly embed automation directly into their existing workflows, enhancing efficiency and consistency.
Also Read:
- Generative AI in Life Sciences Market Poised for Significant Growth, Expected to Reach $1.65 Billion by 2034
- Clarifeye Secures €4 Million Pre-Seed Funding to Scale Expert AI Agents
With this fresh capital, Yseop is poised to scale the adoption of its platform, introduce advanced product capabilities, and expand its global footprint to meet the escalating demand for precise, efficient, and compliant AI solutions across the life sciences sector.
